{
  "pmcid": "6815674",
  "sha256": "c29b3bfea2b7d55159da44e08399740ace739f037c87915492035b4b74c1c0a2",
  "timestamp_utc": "2025-11-09T22:52:07.599158+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.84872951920494,
    "reading_ease": 33.058041901692235,
    "word_count": 219
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of cHuR as a Predictive Marker for Chemotherapy Response in Pancreatic Ductal Adenocarcinoma"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised to receive either gemcitabine (GEM) or 5-fluorouracil (5-FU) as adjuvant monotherapy."
      },
      "Participants": {
        "score": 2,
        "evidence": "379 PDA patients from the European Study Group of Pancreatic Cancer-3 trial were included."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to receive either gemcitabine (GEM) or 5-fluorouracil (5-FU) as adjuvant monotherapy."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluated cytoplasmic HuR (cHuR) as a predictive marker for chemotherapy response in resected pancreatic ductal adenocarcinoma (PDA) patients."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was disease-free survival (DFS), measured over a specified timeframe."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Participants were randomised to receive either gemcitabine (GEM) or 5-fluorouracil (5-FU) as adjuvant monotherapy."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "379 PDA patients from the European Study Group of Pancreatic Cancer-3 trial were included."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "patients with high cHuR expression had significantly greater median DFS with 5-FU compared to GEM (20.1 months, CI: 8.3–36.4 vs 10.9 months, CI: 7.5–14.2; P = 0.04)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      }
    },
    "total_score": 14,
    "max_score": 25
  }
}